The PHASE3 clinical trial NCT06472076, evaluating Pembrolizumab (Keytruda) in combination with placebo for previously untreated PD-L1 high non-small cell lung cancer, completed its primary data collection on 2026-06-30. This study enrolled 88 participants to assess the combination's safety and tolerability.
Background
Pembrolizumab (Keytruda) is being investigated in this study for its use in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC).
Trial design
The PHASE3 study, identified as NCT06472076, enrolled 88 participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC). The trial's goal is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo.
What this means
The primary completion of the PHASE3 trial NCT06472076 signifies that data collection for the main objectives of the study has concluded. Researchers will now proceed with the analysis of the collected safety and tolerability data for the combination of dostarlimab plus belrestotug compared to pembrolizumab plus placebo in patients with PD-L1 high NSCLC. The results will provide insights into the potential role of these therapies in this patient population.
Source
This information was sourced from ClinicalTrials.gov, documenting the primary completion of trial NCT06472076, which occurred on 2026-06-30. The study details are available on clinicaltrials.gov.